02 · The exits → New Zealand
Markets · New Zealand
Why New Zealand.
The regulatory architecture, the company universe, and the exit pathway across the five Necessities in New Zealand.
New Zealand. In-flight regulations by year.
Each bar counts effective dates in New Zealand between 2024 and 2030.
New Zealand is the smallest of the four markets by GDP, population, and venture deployment, and it carries the most concentrated Necessity-aligned regulatory architecture. The regulatory perimeter is deep in three domains that match the country’s economic specialisation: food security, biomedical systems, and power systems. A company that builds at the intersection of one of these and the international export channel holds a regulatory asset that is harder to replicate in larger jurisdictions.
The R&D and grant ecosystem reinforces the alignment. Callaghan Innovation functions are transitioning to MBIE Innovation Services through 2025 and 2026, and the grant pipeline disproportionately supports companies operating near regulatory perimeters, because those are the companies New Zealand industrial policy backs.
New Zealand, current state
- Callaghan Innovation transition: functions transitioning from Callaghan Innovation to MBIE Innovation Services through 2025-2026.1
- Medsafe WAND: among the fastest OECD pathways to Class II medical-device commercial revenue.2
- Renewable share: New Zealand runs a very high share of renewable electricity generation, a natural test bed for grid-edge technology.
- Trans-Tasman alignment: FSANZ food-standards alignment and Medsafe-TGA mutual recognition open the Australian channel and onward export.
Concentrated regulatory architecture
The regulatory architecture is narrower and deeper than larger economies’. Three Necessity-aligned domains are mature; the rest are thinner.
Food security: the Ministry for Primary Industries, AsureQuality verification, the Food Act 2014 compliance regime, Country of Origin labelling, and Food Standards Code updates aligning with FSANZ. Companies that ship dairy, meat, horticulture, or aquaculture into export markets sit inside a verification pathway that is internationally recognised.
Biomedical: Medsafe approval, the Medsafe WAND pathway, the Health and Disability Services Standards, and a software-as-medical-device framework aligning with the TGA. The medtech export channel through Australia and onward to Asia and North America is established and well-trodden.
Power: the Electricity Authority code, the Climate Change Response Act emissions trading scheme, the Emissions Reduction Plan, and renewable-generation deployment policy. The very high renewable share makes the country a natural test bed for grid-edge technologies that export back into larger grid markets.
Adjacent verticals lack the same depth and the same grant alignment.
The grant-aligned regulated share
New Zealand’s R&D ecosystem is grant-led to a degree no other comparable economy matches. Callaghan Innovation, before its transition, distributed material annual funding across direct grants, R&D project funding, and the R&D Tax Incentive process.3 MBIE Innovation Services is now absorbing those functions through 2025 and 2026.
Internal analysis suggests a majority of relevant grant-funded technology companies sit in agritech, medtech, renewable energy, environmental monitoring, and food traceability. The grants are not directed at regulation; they flow disproportionately to companies whose product touches a regulatory perimeter, because those are the companies industrial policy supports. This requires independent verification before being used as an external proof point.
Market reference points
Halter, an Auckland agritech company in the food-security Necessity, has been valued at roughly NZ$2 billion, a public-record outcome that demonstrates the export value a regulatory and verification asset can carry from a small domestic base.4 The medtech and agritech export channels run through Australia and onward to Asia and North America.
Why now
The window is in flight between 2024 and 2030, setting hardest around 2027. The Medsafe WAND pathway is operational, the renewable test-bed conditions are in place, and the Trans-Tasman recognition channel is open. The MBIE transition itself runs through 2025 and 2026, which is the period to monitor.
Risks
The domestic addressable market is too small to support growth from domestic revenue alone. Every New Zealand company in the Necessities is an export company from incorporation. Companies that delay the export build face structural exit risk.
Failure rates run higher than the other three markets. The regulatory asset, when built, has equivalent export value, but the higher base rate is a real market-level feature.
The MBIE transition is a near-term risk. Functional handover between agencies has historically introduced delays in grant disbursement and continuity-of-relationship risk for companies mid-programme.
Footnotes
-
New Zealand Ministry of Business, Innovation and Employment, Innovation Services transition announcement, 2025. Operational handover from Callaghan Innovation continuing through 2026. ↩
-
Medsafe, Web Assisted Notification of Devices (WAND) database and medical-device notification pathway. ↩
-
Callaghan Innovation Annual Reports through FY24. Distribution figures aggregate direct grants and R&D Tax Incentive administration; precise figures vary by year and require independent verification against the official annual report series. ↩
-
Public valuation reporting for Halter. Cited as a market reference point, not a portfolio holding; valuation per public record and subject to change. ↩